<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00487461</url>
  </required_header>
  <id_info>
    <org_study_id>2005-0857</org_study_id>
    <nct_id>NCT00487461</nct_id>
  </id_info>
  <brief_title>Use of Simvastatin for the Prevention of Vasospasm in Aneurysmal Subarachnoid Hemorrhage</brief_title>
  <official_title>Randomized Double Blind Study Using Simvastatin for the PRevention Aof Vasospasm in Aneurysmal Subarachnoid Hemorrhage</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Illinois at Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Illinois at Chicago</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test whether treatment with a drug called Simvastatin
      prevents and improves outcome in patients who have Subarachnoid bleeding. Simvastatin is
      currently approved for the treatment of high cholesterol levels.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aneurysmal Subarachnoid hemorrhage or SAH (bleeding on the surface of the brain) affects 10
      per 100,000 population each year. For survivors of the initial hemorrhage, delayed narrowing
      of the blood vessels (vasospasm) and related delayed strokes are the most common serious
      complication. Narrowing of blood vessels affect 30% of patients with such bleeding. Despite
      maximum therapy, nearly 50% of patients with symptomatic vasospasm with develop stroke.
      Because cerebral vasospasm remains the leading cause of morbidity and mortality after aSAH,
      this critically important issue needs further studies.

      One hundred and fifty patients will be randomized, 50 to each arm of the study. Patients
      enrolled in the study will be receive the drug (either Simvastatin 40 mg or Simvastatin 80 mg
      per mouth daily), while the control group will receive a sugar tablet. The treatment will be
      continued for a total of 21 days. The neurological abilities (Stroke Outcome measures, these
      are included with the application for your review) at day 21 post aSAH will be reviewed at
      time of discharge as well at 6 months of follow up.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study PI left the institution and study was stopped at that time.
  </why_stopped>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To Measure Outcome in Patients Diagnosed With Aneurysmal Subarachnoid Hemorrhage (aSAH) Treated With Simvastatin, by Assessing Neurological Outcome by Accessing Glasgow Outcome Score, Modified Rankin Scale, and Barthel Index Score at Day 21 Post aSAH</measure>
    <time_frame>21 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To Determine Efficiency of Simvastatin in Decreasing the Incidence of Clinical Vasospasm in aSAH, and Define the Optimal Dose of Simvastatin and to Measure Outcome at 6 Months Follow up</measure>
    <time_frame>6 months</time_frame>
    <description>Study PI left before the efficacy of Simvastatin decreasing the incidence of clinical vasospasm in aSAH, and defining the optimal dose of Simvastatin and measuring the outcome at 6 months follow up data was collected for the study and therefore these outcomes will never be analyzed.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Aneurysmal Subarachnoid Hemorrhage</condition>
  <condition>Cerebral Vasospasm</condition>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study Group #1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Simvastatin 40 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study Group #2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Simvastatin 80 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simvastatin 40 mg</intervention_name>
    <description>Comparing two doses of Simvastatin to placebo</description>
    <arm_group_label>Study Group #1</arm_group_label>
    <other_name>Zocor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablet</description>
    <arm_group_label>Control Group</arm_group_label>
    <other_name>dummy pill, sugar pill</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simvastatin 80 mg</intervention_name>
    <description>Comparing two doses of Simvastatin to placebo</description>
    <arm_group_label>Study Group #2</arm_group_label>
    <other_name>Zocor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-85 years old inclusive

          -  Subarachnoid hemorrhage diagnosed by CT on admission

          -  Randomizable within 732 hours of subarachnoid hemorrhage

          -  Saccular intracranial aneurysm proven by cerebral angiography or computed tomographic
             angiography (CTA)

          -  Surgical or endovascular obliteration

          -  Able to obtain written informed consent from patient or surrogate

        Exclusion Criteria:

          -  Pregnancy, as confirmed by routine urine test on admission

          -  Elevated liver function test at time of randomization, defined as more than three
             times the upper limit of normal

          -  On Statins, niacin, or fibrate therapy within 30 days of presentation

          -  Any vasospasm on the initial diagnostic angiogram

          -  Glasgow Coma Scale 5 or less at the time of randomization

          -  History of liver disease or active liver disease

          -  Hypersensitivity to statins

          -  Patient taking medication not recommended for concomitant use with Simvastatin (40 or
             80 mg) as per the product label
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ben Z. Roitberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assnt Prof. Univ. of Illinois at Chicago, Dept of Neurosurgery</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ali Alaraj, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Fellow Department of Neurosurgery</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Univeristy of Illinois at Chicago, Dept of Neurosurgery</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 15, 2007</study_first_submitted>
  <study_first_submitted_qc>June 15, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 18, 2007</study_first_posted>
  <results_first_submitted>July 22, 2015</results_first_submitted>
  <results_first_submitted_qc>October 22, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 25, 2015</results_first_posted>
  <last_update_submitted>October 22, 2015</last_update_submitted>
  <last_update_submitted_qc>October 22, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 25, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Illinois at Chicago</investigator_affiliation>
    <investigator_full_name>Ali Alaraj</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>SAH</keyword>
  <keyword>Vasospasm</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Subarachnoid Hemorrhage</mesh_term>
    <mesh_term>Vasospasm, Intracranial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simvastatin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Control Group</title>
          <description>Placebo tablet
Placebo: Placebo tablet</description>
        </group>
        <group group_id="P2">
          <title>Study Group #1</title>
          <description>Simvastatin 40 mg
Simvastatin: Comparing two doses of Simvastatin to placebo</description>
        </group>
        <group group_id="P3">
          <title>Study Group #2</title>
          <description>Simvastatin 80 mg
Simvastatin: Comparing two doses of Simvastatin to placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Control Group</title>
          <description>Placebo tablet
Placebo: Placebo tablet</description>
        </group>
        <group group_id="B2">
          <title>Study Group #1</title>
          <description>Simvastatin 40 mg
Simvastatin: Comparing two doses of Simvastatin to placebo</description>
        </group>
        <group group_id="B3">
          <title>Study Group #2</title>
          <description>Simvastatin 80 mg
Simvastatin: Comparing two doses of Simvastatin to placebo</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="11"/>
            <count group_id="B4" value="25"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57" spread="5.6"/>
                    <measurement group_id="B2" value="47" spread="10.7"/>
                    <measurement group_id="B3" value="50" spread="11.6"/>
                    <measurement group_id="B4" value="49" spread="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&gt; 70 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60-70 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>50-60 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>40-50 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt; 40 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>To Measure Outcome in Patients Diagnosed With Aneurysmal Subarachnoid Hemorrhage (aSAH) Treated With Simvastatin, by Assessing Neurological Outcome by Accessing Glasgow Outcome Score, Modified Rankin Scale, and Barthel Index Score at Day 21 Post aSAH</title>
        <time_frame>21 days</time_frame>
        <population>Study PI left before outcome data was collected for the study and therefore the Outcome(s) will never be analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Control Group</title>
            <description>Placebo tablet
Placebo: Placebo tablet</description>
          </group>
          <group group_id="O2">
            <title>Study Group #1</title>
            <description>Simvastatin 40 mg
Simvastatin: Comparing two doses of Simvastatin to placebo</description>
          </group>
          <group group_id="O3">
            <title>Study Group #2</title>
            <description>Simvastatin 80 mg
Simvastatin: Comparing two doses of Simvastatin to placebo</description>
          </group>
        </group_list>
        <measure>
          <title>To Measure Outcome in Patients Diagnosed With Aneurysmal Subarachnoid Hemorrhage (aSAH) Treated With Simvastatin, by Assessing Neurological Outcome by Accessing Glasgow Outcome Score, Modified Rankin Scale, and Barthel Index Score at Day 21 Post aSAH</title>
          <population>Study PI left before outcome data was collected for the study and therefore the Outcome(s) will never be analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Determine Efficiency of Simvastatin in Decreasing the Incidence of Clinical Vasospasm in aSAH, and Define the Optimal Dose of Simvastatin and to Measure Outcome at 6 Months Follow up</title>
        <description>Study PI left before the efficacy of Simvastatin decreasing the incidence of clinical vasospasm in aSAH, and defining the optimal dose of Simvastatin and measuring the outcome at 6 months follow up data was collected for the study and therefore these outcomes will never be analyzed.</description>
        <time_frame>6 months</time_frame>
        <population>Study PI left before the efficacy of Simvastatin decreasing the incidence of clinical vasospasm in aSAH, and defining the optimal dose of Simvastatin and measuring the outcome at 6 months follow up data was collected for the study and therefore these outcomes will never be analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Control Group</title>
            <description>Placebo tablet
Placebo: Placebo tablet</description>
          </group>
          <group group_id="O2">
            <title>Study Group #1</title>
            <description>Simvastatin 40 mg
Simvastatin: Comparing two doses of Simvastatin to placebo</description>
          </group>
          <group group_id="O3">
            <title>Study Group #2</title>
            <description>Simvastatin 80 mg
Simvastatin: Comparing two doses of Simvastatin to placebo</description>
          </group>
        </group_list>
        <measure>
          <title>To Determine Efficiency of Simvastatin in Decreasing the Incidence of Clinical Vasospasm in aSAH, and Define the Optimal Dose of Simvastatin and to Measure Outcome at 6 Months Follow up</title>
          <description>Study PI left before the efficacy of Simvastatin decreasing the incidence of clinical vasospasm in aSAH, and defining the optimal dose of Simvastatin and measuring the outcome at 6 months follow up data was collected for the study and therefore these outcomes will never be analyzed.</description>
          <population>Study PI left before the efficacy of Simvastatin decreasing the incidence of clinical vasospasm in aSAH, and defining the optimal dose of Simvastatin and measuring the outcome at 6 months follow up data was collected for the study and therefore these outcomes will never be analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Serious and Other (Not Including Serious) Adverse Events were not collected/assessed.</desc>
      <group_list>
        <group group_id="E1">
          <title>Control Group</title>
          <description>Placebo tablet
Placebo: Placebo tablet</description>
        </group>
        <group group_id="E2">
          <title>Study Group #1</title>
          <description>Simvastatin 40 mg
Simvastatin: Comparing two doses of Simvastatin to placebo</description>
        </group>
        <group group_id="E3">
          <title>Study Group #2</title>
          <description>Simvastatin 80 mg
Simvastatin: Comparing two doses of Simvastatin to placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early termination leading to small numbers of subjects analyzed and Primary Physician leaving institution before study completion.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Ali Alaraj, MD</name_or_title>
      <organization>University of Illinois at Chicago</organization>
      <phone>312-996-4842</phone>
      <email>alaraj@uic.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

